When people hear about a promising new medicine that isn't yet available, one question often follows:
"Can I get it?"
The answer depends on something many patients have never heard of.
There are two very different pathways that may provide access to investigational treatments:
- participating in a clinical trial, or
- receiving treatment through an Early Access (Expanded Access/Compassionate Use) program.
Although both involve medicines that have not yet received full regulatory approval, they serve very different purposes.
Understanding the difference can help patients ask better questions and explore all available options.
Clinical Trials Generate Evidence
Clinical trials exist to answer scientific questions.
Researchers study whether a new treatment is safe, whether it works better than existing therapies, and which patients benefit the most.
Because the goal is to produce reliable scientific evidence, clinical trials follow strict protocols. Participants must meet detailed eligibility criteria, attend scheduled visits, undergo regular testing, and follow study procedures.
Not everyone who wants to participate will qualify.
In fact, many patients are excluded because of previous treatments, other medical conditions, laboratory results, or disease characteristics.
The FDA provides a detailed overview of how clinical trials are designed and why eligibility criteria are necessary.
Early Access Is Different
Early Access programs—also known as Expanded Access in the US or Compassionate Use in many other countries—have a different purpose.
Instead of answering research questions, these programs are designed to provide treatment to patients with serious or life-threatening diseases who have exhausted available options and cannot participate in an appropriate clinical trial.
Unlike clinical trials, Early Access is not research. The primary goal is patient treatment rather than collecting data for regulatory approval.
In Europe, Compassionate Use programs are coordinated under guidance from the European Medicines Agency (EMA).
Does Early Access Mean Anyone Can Receive an Investigational Drug?
Unfortunately, no.
Many patients assume that once a medicine shows promising results, it becomes available through Early Access.
In reality, several conditions usually need to be met.
The treating physician must believe the potential benefits outweigh the risks.
The pharmaceutical company must agree to provide the medicine.
Regulatory authorities may need to authorize its use.
And in many countries, specific legal frameworks determine whether Early Access programs are available at all.
In other words, eligibility depends on much more than simply requesting the treatment.
Why Some Patients Cannot Join Clinical Trials
One common misconception is that patients turn to Early Access only after refusing a clinical trial.
In reality, many patients would gladly participate—but simply do not qualify.
Common reasons include:
- previous treatments that make them ineligible,
- medical conditions that increase safety risks,
- laboratory values outside protocol requirements,
- lack of an enrolling study nearby,
- or a trial that has already completed enrollment.
For these patients, Early Access may become one of the few remaining possibilities to receive an investigational therapy.
Clinical Trials Usually Come First
Whenever an appropriate clinical trial is available, it is generally considered the preferred pathway.
Clinical trials provide structured monitoring, generate evidence that helps future patients, and are often specifically designed for the patient's disease.
Many regulatory agencies recommend considering clinical trial participation before pursuing Expanded Access.
Questions Worth Asking Your Doctor
If you're considering investigational treatment, it may help to ask:
- Am I eligible for any clinical trials?
- If not, why?
- Are there trials available at other hospitals or in other regions?
- Could an Early Access or Compassionate Use program be appropriate for me?
- Has the manufacturer established such a program?
- Would seeking a second opinion help identify additional options?
These questions may open conversations that would not otherwise happen.
The Bottom Line
Clinical trials and Early Access programs are not competitors.
They are complementary pathways designed for different situations.
Clinical trials help determine whether new treatments work.
Early Access may provide treatment when research participation is no longer possible.
Understanding the difference allows patients to have more informed conversations with their healthcare team and better navigate a complex treatment landscape.
Right2Hope Perspective
At Right2Hope, we believe every patient deserves to understand all potential pathways—not just the one presented during a clinic visit.
Knowing the difference between a clinical trial and an Early Access program may not change a diagnosis.
But it can change the questions you ask.
And sometimes, asking the right question is where a new opportunity begins.